UK Drug Pricing Talks Collapse, Threatening Pharma Investment

Negotiations on drug pricing between the UK government and major drugmakers have broken down, with the industry warning that future investment is at risk. The government had offered to increase spending on medicines and lower the rebate rate, but the industry wanted a lower rebate rate and changes to take effect sooner. The failure to reach a deal has left the UK "deeply uncompetitive" for life sciences investment, according to Novartis AG's UK president.